<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12069980
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     06
    </month>
    <day>
     18
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     01
    </month>
    <day>
     03
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2010
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0066-4804
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       46
      </volume>
      <issue>
       7
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Jul
       </month>
      </pubdate>
     </journalissue>
     <title>
      Antimicrobial agents and chemotherapy
     </title>
     <isoabbreviation>
      Antimicrob. Agents Chemother.
     </isoabbreviation>
    </journal>
    <articletitle>
     Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.
    </articletitle>
    <pagination>
     <medlinepgn>
      2238-43
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Acyclovir cream has been available for the treatment of herpes labialis in numerous countries outside the United States for over a decade. Evidence for its efficacy comes from a few small clinical trials conducted in the 1980s. To examine more comprehensively the efficacy and safety of this formulation, we conducted two independent, identical, parallel, randomized, double-blind, vehicle-controlled, large-scale multicenter clinical trials. Healthy adults with a history of frequent herpes labialis were recruited from the general population, screened for eligibility, randomized equally to 5% acyclovir cream or vehicle control, given study medication, and told to self-initiate treatment five times daily for 4 days beginning within 1 h of the onset of a recurrent episode. The number of patients who treated a lesion was 686 in study 1 and 699 in study 2. In study 1, the mean duration of episodes was 4.3 days for patients treated with acyclovir cream and 4.8 days for those treated with the vehicle control (hazards ratio [HR] = 1.23; 95% confidence interval [CI], 1.06 to 1.44; P = 0.007). In study 2, the mean duration of episodes was 4.6 days for patients treated with acyclovir cream and 5.2 days for those treated with the vehicle control (HR = 1.24; 95% CI, 1.06 to 1.44; P = 0.006). Efficacy was apparent whether therapy was initiated "early" (prodrome or erythema lesion stage) or "late" (papule or vesicle stage). There was a statistically significant reduction in the duration of lesion pain in both studies. Acyclovir cream did not prevent the development of classical lesions (progression to vesicles, ulcers, and/or crusts). Adverse events were mild and infrequent.
     </abstracttext>
    </abstract>
    <affiliation>
     Division of Infectious Diseases, University of Utah, Salt Lake City, Utah 84132, USA. woody.spruance@hsc.utah.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Spruance
      </lastname>
      <forename>
       Spotswood L
      </forename>
      <initials>
       SL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Nett
      </lastname>
      <forename>
       Robert
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Marbury
      </lastname>
      <forename>
       Thomas
      </forename>
      <initials>
       T
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wolff
      </lastname>
      <forename>
       Ray
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Johnson
      </lastname>
      <forename>
       James
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Spaulding
      </lastname>
      <forename>
       Theodore
      </forename>
      <initials>
       T
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Antimicrob Agents Chemother
    </medlineta>
    <nlmuniqueid>
     0315061
    </nlmuniqueid>
    <issnlinking>
     0066-4804
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antiviral Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Ointments
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pharmaceutical Vehicles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      39809-25-1
     </registrynumber>
     <nameofsubstance>
      penciclovir
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      54-42-2
     </registrynumber>
     <nameofsubstance>
      Idoxuridine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      59277-89-3
     </registrynumber>
     <nameofsubstance>
      Acyclovir
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1990 Feb;161(2):185-90
     </refsource>
     <pmid version="1">
      2153735
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1997 May 7;277(17):1374-9
     </refsource>
     <pmid version="1">
      9134943
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Oral Surg Oral Med Oral Pathol. 1989 Jun;67(6):676-9
     </refsource>
     <pmid version="1">
      2740091
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Antimicrob Agents Chemother. 1986 May;29(5):730-2
     </refsource>
     <pmid version="1">
      3729337
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br Med J (Clin Res Ed). 1985 Jul 6;291(6487):7-9
     </refsource>
     <pmid version="1">
      3926067
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1985 May;102(5):632-3
     </refsource>
     <pmid version="1">
      3985514
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1984 Sep;150(3):323-9
     </refsource>
     <pmid version="1">
      6090539
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Oral Surg Oral Med Oral Pathol. 1984 Dec;58(6):667-71
     </refsource>
     <pmid version="1">
      6095159
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br J Dermatol. 1983 Sep;109(3):321-6
     </refsource>
     <pmid version="1">
      6351894
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br Med J (Clin Res Ed). 1983 May 28;286(6379):1699-701
     </refsource>
     <pmid version="1">
      6405939
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Antimicrob Agents Chemother. 1984 Dec;26(6):819-23
     </refsource>
     <pmid version="1">
      6441511
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Antimicrob Agents Chemother. 1984 Jan;25(1):10-5
     </refsource>
     <pmid version="1">
      6703671
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Antimicrob Agents Chemother. 1984 May;25(5):553-5
     </refsource>
     <pmid version="1">
      6732224
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1982 Jul;146(1):85-90
     </refsource>
     <pmid version="1">
      7045255
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1993 Feb 15;118(4):268-72
     </refsource>
     <pmid version="1">
      8380540
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1990 Feb;161(2):191-7
     </refsource>
     <pmid version="1">
      2153736
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Acyclovir
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antiviral Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Herpes Labialis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Idoxuridine
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ointments
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pharmaceutical Vehicles
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC127288
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      6
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      1
     </month>
     <day>
      4
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      6
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12069980
    </articleid>
    <articleid idtype="pmc">
     PMC127288
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

